Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection
Leuk Lymphoma
.
2022 Jan;63(1):253-255.
doi: 10.1080/10428194.2021.1978086.
Epub 2021 Sep 15.
Authors
Arthur Poncelet
1
,
Gil Verschelden
2
,
Martin Colard
1
,
Marc Hildebrand
3
,
Maya Hites
2
,
Nicolas Yin
4
,
Charlotte Michel
4
,
David Grimaldi
5
,
Virginie De Wilde
1
Affiliations
1
Departement of Hematology, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
2
Clinic of Infectious Disease, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
3
Department of Internal Medicine, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
4
Department of Microbiology, Laboratoire hospitalier universitaire de Bruxelles (LHUB-ULB)- Université libre de Bruxelles, Brussels, Belgium.
5
Departement of Intensive Care, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
PMID:
34521312
DOI:
10.1080/10428194.2021.1978086
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Viral
COVID-19*
Humans
SARS-CoV-2
Substances
Antibodies, Viral